Evaluation of commercially available reagents for diagnosis of histoplasmosis infection in immunocompromised patients.
about
Reevaluation of commercial reagents for detection of Histoplasma capsulatum antigen in urineUpdate on fungal diagnostics.Laboratory Diagnostics for Histoplasmosis.Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps.Standardization and validation of real time PCR assays for the diagnosis of histoplasmosis using three molecular targets in an animal model.Evaluation of two new enzyme immunoassay reagents for diagnosis of histoplasmosis in a cohort of clinically characterized patients.Multicenter validation of commercial antigenuria reagents to diagnose progressive disseminated histoplasmosis in people living with HIV/AIDS in two Latin American countries.
P2860
Q35193210-3F9BE50F-74D3-4E45-A07B-C5744A6DA385Q38217351-D01E8FC0-41E5-4F5D-83EB-B4869375E214Q39169374-492C3B73-7127-479B-AC62-96A1537E83CCQ42584304-A9D87766-C0ED-4C08-9082-705ECE6ECD9BQ47245207-13C68A6F-08C4-47F0-8377-FFB743D7975DQ51784835-7E0675AB-B580-40A4-8380-C05B9C236C44Q54251498-F047FC97-64E7-4A27-B586-A072C0A9567A
P2860
Evaluation of commercially available reagents for diagnosis of histoplasmosis infection in immunocompromised patients.
description
2013 թվականի հոկտեմբերի 2-ին հրատարակված գիտական հոդված
@hy
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
Evaluation of commercially ava ...... in immunocompromised patients.
@en
Evaluation of commercially ava ...... in immunocompromised patients.
@nl
type
label
Evaluation of commercially ava ...... in immunocompromised patients.
@en
Evaluation of commercially ava ...... in immunocompromised patients.
@nl
prefLabel
Evaluation of commercially ava ...... in immunocompromised patients.
@en
Evaluation of commercially ava ...... in immunocompromised patients.
@nl
P2093
P2860
P356
P1476
Evaluation of commercially ava ...... in immunocompromised patients.
@en
P2093
Bill Gibson
Thomas M Daly
Xiaochun Zhang
P2860
P304
P356
10.1128/JCM.02298-13
P407
P577
2013-10-02T00:00:00Z